A [32P]NAD+-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitors

Analytical Biochemistry

Volumn 474, Issue , 2015, Pages 40-49

  Yu, Weixuan ^a   Neckles, Carla ^a   Chang, Andrew ^a   Bommineni, Gopal Reddy ^a   Spagnuolo, Lauren ^a   Zhang, Zhuo ^a   Liu, Nina ^a   Lai, Christina ^b   Truglio, James ^b   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Great Neck South High School   (United States)

Author keywords

Enoyl ACP reductase; High throughput screening; Methodology; Penefsky column; Residence time (tR); Steady state kinetics

Indexed keywords

ENZYME ACTIVITY;

ENOYL ACP REDUCTASE; HIGH THROUGHPUT SCREENING; METHODOLOGY; RESIDENCE TIME; STEADY-STATE KINETICS;

KINETICS;

ADENYLATE NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE P 32; BACTERIAL ENZYME; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADPH); FABI ENZYME; FABI INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ACYL CARRIER PROTEIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHOSPHORUS;

ARTICLE; CONCENTRATION RESPONSE; DISSOCIATION CONSTANT; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STABILITY; GEL FILTRATION; HIGH THROUGHPUT SCREENING; HUMAN; ISOTOPE LABELING; LIMIT OF QUANTITATION; LONG RESIDENCE TIME; MATHEMATICAL MODEL; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE; SURFACE PLASMON RESONANCE; TEMPERATURE MEASUREMENT; ANTAGONISTS AND INHIBITORS; BIOCHEMISTRY; COMPUTER SIMULATION; FEASIBILITY STUDY; KINETICS; METABOLISM; PROCEDURES; REPRODUCIBILITY; TEMPERATURE; TIME;

ACYL CARRIER PROTEIN; BIOCHEMISTRY; COMPUTER SIMULATION; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; FEASIBILITY STUDIES; HIGH-THROUGHPUT SCREENING ASSAYS; KINETICS; NAD; PHOSPHORUS RADIOISOTOPES; REPRODUCIBILITY OF RESULTS; TEMPERATURE; TIME FACTORS;

EID: 84923380412     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2014.12.022     Document Type: Article

References (46)

1. G. Taubes The bacteria fight back Science 321 2008 356 361
2. D. McDevitt, and M. Rosenberg Exploiting genomics to discover new antibiotics Trends Microbiol. 9 2001 611 617
3. E. Marshall Trench warfare in a battle with TB Science 321 2008 362 364
4. G.D. Wright The antibiotic resistome: the nexus of chemical and genetic diversity Nat. Rev. Microbiol. 5 2007 175 186
5. R.A. Copeland, D.L. Pompliano, and T.D. Meek Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discov. 5 2006 730 739
6. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492
7. G. Vauquelin, and S.J. Charlton Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 161 2010 488 508
8. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
9. H. Lu, K. England, C. am Ende, J.J. Truglio, S. Luckner, B.G. Reddy, N.L. Marlenee, S.E. Knudson, D.L. Knudson, R.A. Bowen, C. Kisker, R.A. Slayden, and P.J. Tonge Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity ACS Chem. Biol. 4 2009 221 231
10. H. Lu, and P.J. Tonge Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 14 2010 467 474
11. G.S. Van Aller, R. Nandigama, C.M. Petit, W.E. DeWolf Jr., C.J. Quinn, K.M. Aubart, M. Zalacain, S.B. Christensen, R.A. Copeland, and Z. Lai Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin Biochemistry 44 2005 253 260
12. R.A. Copeland, A. Basavapathruni, M. Moyer, and M.P. Scott Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis Anal. Biochem. 416 2011 206 210
13. R. Rajagopalan, S. Misialek, S.K. Stevens, D.G. Myszka, B.J. Brandhuber, J.A. Ballard, S.W. Andrews, S.D. Seiwert, and K. Kossen Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior Biochemistry 48 2009 2559 2568
14. M.A. Cooper Advances in membrane receptor screening and analysis J. Mol. Recognit. 17 2004 286 315
15. R.L. Rich, and D.G. Myszka Advances in surface plasmon resonance biosensor analysis Curr. Opin. Biotechnol. 11 2000 54 61
16. D.G. Myszka, and R.L. Rich Implementing surface plasmon resonance biosensors in drug discovery Pharm. Sci. Technol. Today 3 2000 310 317
17. Y. Abdiche, D. Malashock, A. Pinkerton, and J. Pons Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet Anal. Biochem. 377 2008 209 217
18. R. Karlsson, P.S. Katsamba, H. Nordin, E. Pol, and D.G. Myszka Analyzing a kinetic titration series using affinity biosensors Anal. Biochem. 349 2006 136 147
19. S.B.H.Q. Zhang, and N.J. Tao High-performance differential surface plasmon resonance sensor using quadrant cell photodetector Rev. Sci. Instrum. 74 2003 150 153
20. H.S. Penefsky Reversible binding of Pi by beef heart mitochondrial adenosine triphosphatase J. Biol. Chem. 252 1977 2891 2899
21. H.S. Penefsky A centrifuged-column procedure for the measurement of ligand binding by beef heart F1 Methods Enzymol. 56 1979 527 530
22. B. Tillotson, K. Slocum, J. Coco, N. Whitebread, B. Thomas, K.A. West, J. MacDougall, J. Ge, J.A. Ali, V.J. Palombella, E. Normant, J. Adams, and C.C. Fritz Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo J. Biol. Chem. 285 2010 39835 39843
23. A. Quemard, J.C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W.R. Jacobs Jr., and J.S. Blanchard Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis Biochemistry 34 1995 8235 8241
24. W.H. Ward, G.A. Holdgate, S. Rowsell, E.G. McLean, R.A. Pauptit, E. Clayton, W.W. Nichols, J.G. Colls, C.A. Minshull, D.A. Jude, A. Mistry, D. Timms, R. Camble, N.J. Hales, C.J. Britton, and I.W. Taylor Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan Biochemistry 38 1999 12514 12525
25. N. Liu, J.E. Cummings, K. England, R.A. Slayden, and P.J. Tonge Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei J. Antimicrob. Chemother. 66 2011 564 573
26. H. Xu, T.J. Sullivan, J. Sekiguchi, T. Kirikae, I. Ojima, C.F. Stratton, W. Mao, F.L. Rock, M.R. Alley, F. Johnson, S.G. Walker, and P.J. Tonge Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus Biochemistry 47 2008 4228 4236
27. S.R. Luckner, N. Liu, C.W. am Ende, P.J. Tonge, and C. Kisker A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis J. Biol. Chem. 285 2010 14330 14337
28. J. Schiebel, A. Chang, H. Lu, M.V. Baxter, P.J. Tonge, and C. Kisker Staphylococcus aureus Fab I: inhibition, substrate recognition, and potential implications for in vivo essentiality Structure 20 2012 802 813
29. S. Parikh, D.P. Moynihan, G. Xiao, and P.J. Tonge Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis Biochemistry 38 1999 13623 13634
30. C.W. am Ende, S.E. Knudson, N. Liu, J. Childs, T.J. Sullivan, M. Boyne, H. Xu, Y. Gegina, D.L. Knudson, F. Johnson, C.A. Peloquin, R.A. Slayden, and P.J. Tonge Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors Bioorg. Med. Chem. Lett. 18 2008 3029 3033
31. S. Sivaraman, T.J. Sullivan, F. Johnson, P. Novichenok, G. Cui, C. Simmerling, and P.J. Tonge Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues J. Med. Chem. 47 2004 509 518
32. T.J. Sullivan, J.J. Truglio, M.E. Boyne, P. Novichenok, X. Zhang, C.F. Stratton, H.J. Li, T. Kaur, A. Amin, F. Johnson, R.A. Slayden, C. Kisker, and P.J. Tonge High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis ACS Chem. Biol. 1 2006 43 53
33. P. Pan, Lead optimization and slow-onset inhibition of the enoyl-ACP reductase (InhA) from Mycobacterium tuberculosis (Ph.D. dissertation), Stony Brook University, 2012.
34. A. Chang, J. Schiebel, W. Yu, G.R. Bommineni, P. Pan, M.V. Baxter, A. Khanna, C.A. Sotriffer, C. Kisker, and P.J. Tonge Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex Biochemistry 52 2013 4217 4228
35. R. Rawat, A. Whitty, and P.J. Tonge The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance Proc. Natl. Acad. Sci. U.S.A. 100 2003 13881 13886
36. A. Wang, C. Dorso, L. Kopcho, G. Locke, R. Langish, E. Harstad, P. Shipkova, J. Marcinkeviciene, L. Hamann, and M.S. Kirby Potency, selectivity, and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor BMC Pharmacol. 12 2012 2
37. K. Anderson, Z. Lai, O.B. McDonald, J.D. Stuart, E.N. Nartey, M.A. Hardwicke, K. Newlander, D. Dhanak, J. Adams, D. Patrick, R.A. Copeland, P.J. Tummino, and J. Yang Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1 Biochem. J. 420 2009 259 265
38. E.P. Garvey, B. Schwartz, M.J. Gartland, S. Lang, W. Halsey, G. Sathe, H.L. Carter 3rd, and K.L. Weaver Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant Biochemistry 48 2009 1644 1653
39. R.A. Copeland Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists second ed. 2005 John Wiley Hoboken, NJ
40. G. Vauquelin, and I. Van Liefde Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems Expert Opin. Drug Discov. 7 2012 583 595
41. J.T. Wu, L.H. Wu, and J.A. Knight Stability of NADPH: effect of various factors on the kinetics of degradation Clin. Chem. 32 1986 314 319
42. D. Hofmann, A. Wirtz, B. Santiago-Schubel, U. Disko, and M. Pohl Structure elucidation of the thermal degradation products of the nucleotide cofactors NADH and NADPH by nano-ESI-FTICR-MS and HPLC-MS Anal. Bioanal. Chem. 398 2010 2803 2811
43. L.T. Gooljarsingh, C. Fernandes, K. Yan, H. Zhang, M. Grooms, K. Johanson, R.H. Sinnamon, R.B. Kirkpatrick, J. Kerrigan, T. Lewis, M. Arnone, A.J. King, Z. Lai, R.A. Copeland, and P.J. Tummino A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues Proc. Natl. Acad. Sci. U.S.A. 103 2006 7625 7630
44. J.C. Uitdehaag, C.M. Sunnen, A.M. van Doornmalen, N. de Rouw, A. Oubrie, R. Azevedo, M. Ziebell, E. Nickbarg, W.J. Karstens, and S. Ruygrok Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way J. Biomol. Screen. 16 2011 1007 1017
45. G. Vauquelin Determination of drug-receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance Med. Chem. Commun. 3 2012 645 651
46. H.J. Motulsky, and L.C. Mahan The kinetics of competitive radioligand binding predicted by the law of mass action Mol. Pharmacol. 25 1984 1 9